⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10857569 | 0.96 | — | — | |
| SCHEMBL14075638 | 0.74 | — | — | |
| SCHEMBL8974353 | 0.74 | — | — | |
| SCHEMBL11855457 | 0.74 | — | — | |
| SCHEMBL5839804 | 0.72 | — | — | |
| SCHEMBL10189428 | 0.67 | — | — | |
| SCHEMBL14198435 | 0.67 | — | — | |
| SCHEMBL11080754 | 0.67 | — | — | |
| SCHEMBL14198228 | 0.67 | — | — | |
| SCHEMBL18618088 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | claimed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | claimed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | claimed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | claimed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| CN-106795104-A | Improved process for preparing high purity metformin | 瑟勒特·库玛·卡玛瓦拉普 | 2017-05-31 | — | — | CN | disclosed |
| US-20140357599-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2014-12-04 | — | — | US | disclosed |
| US-8871747-B2 | Urea and thiourea derivatives | TOPOTARGET A/S (DK) | 2014-10-28 | — | — | US | disclosed |
| US-8372802-B2 | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120010172-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | MCDERMOTT WILL & EMERY LLP (DC) | 2012-01-12 | — | — | US | disclosed |
| EP-2342181-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | Topo Target A/S (DK) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010023307-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | TOPOTARGET A/S (DK) | 2010-03-04 | — | — | WO | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-5294708-A | Antidiabetic agents | MCNEILAB, INC. (US) | 1994-03-15 | — | — | US | disclosed |
| US-5268373-A | Containing a benzene ring | MCNEILAB, INC. (US) | 1993-12-07 | — | — | US | disclosed |
| EP-0121082-A1 | Guanidin derivatives | BAYER AG (DE) | 1984-10-10 | — | — | EP | disclosed |